L1-10 / Amgen - LARVOL DELTA

SHort Of Pace - Heart Failure (SHOP-HF) (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

New trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (clinicaltrials.gov) - P2; N=22; Not yet recruiting; Sponsor: National Cancer Center, Korea

New P2 trial

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (clinicaltrials.gov) - P2; N=22; Recruiting; Sponsor: National Cancer Center, Korea; Not yet recruiting ➔ Recruiting

Enrollment open